Drug intelligence / Profile preview

PTX-204

Development stage: Preclinical
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

PTX-204 is a multiantigen mRNA vaccine candidate developed by Providence Therapeutics for the prevention of malaria. It utilizes mRNA technology to encode several antigens derived from the *Plasmodium* parasite, aiming to elicit a broad and protective immune response. The vaccine is designed to target the parasite at multiple stages of its life cycle to improve efficacy compared to single-antigen approaches. Currently, PTX-204 is in the discovery phase of development.

Beyond the preview

Go deeper on PTX-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-204.

Explore the full profile